Pfizer does not infringe Synthon IP patent for amlodipine process, jury rules unanimously

By Lisa Kerner

Charlotte, N.C., Aug. 17 - A federal court jury in the Easter District of Virginia ruled unanimously that Pfizer Inc. does not infringe Synthon IP's U.S. patent covering a process for making amlodipine, the active ingredient in Norvasc, the world's most-prescribed branded medicine for hypertension.

In addition, the jury found that the patent is invalid, according to a company news release.

Synthon IP, a U.S. subsidiary of Dutch company Synthon BV, brought its suit against Pfizer in November 2005.

Pfizer is a pharmaceutical company based in New York.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.